Characterization of Effusion-Infiltrating T Cells: Benign versus Malignant Effusions

D Atanackovic, A Block, A de Weerth, C Faltz… - Clinical Cancer …, 2004 - AACR
D Atanackovic, A Block, A de Weerth, C Faltz, DK Hossfeld, S Hegewisch-Becker
Clinical Cancer Research, 2004AACR
Purpose: While naïve T cells circulate between peripheral blood and lymph nodes,
memory effector T cells acquire certain surface molecules that enable them to travel to
peripheral tissues and exert their effector function. We analyzed whether deficient numbers
of effector-type T cells within the malignant effusion might contribute to tumor escape from
immunosurveillance. Experimental Design: We analyzed the expression of a broad range of
adhesion molecules and chemokine receptors (CD62L, CD56, CCR4, CCR5, CCR7 …
Abstract
Purpose: While naïve T cells circulate between peripheral blood and lymph nodes, memory effector T cells acquire certain surface molecules that enable them to travel to peripheral tissues and exert their effector function. We analyzed whether deficient numbers of effector-type T cells within the malignant effusion might contribute to tumor escape from immunosurveillance.
Experimental Design: We analyzed the expression of a broad range of adhesion molecules and chemokine receptors (CD62L, CD56, CCR4, CCR5, CCR7, CXCR3, CLA, and integrin α4β7) on tumor-associated lymphocytes in effusions and peripheral blood lymphocytes of patients with malignant ascites (n = 11) or malignant pleural effusion (n = 16). A tumor-associated lymphocyte:peripheral blood lymphocyte ratio was calculated as an indicator for homing of lymphocytes into the effusions and was compared with patients with nonmalignant ascites (n = 17).
Results: Patients with malignancies show an increased enrichment of T cells expressing the phenotype of “naïve” (CD62L+ and CD45RA+CCR7+), “central memory” (CD45RA-CCR7+), and type 2-polarized (CCR4+) T cells within their effusions. In contrast, enrichment of “effector”-type (CD45RA-CCR7− or CD45RA+CCR7−) and presumably type 1-polarized T cells (CCR5+) at the tumor site is deficient. The same is true for natural killer cells and potentially cytotoxic CD56+ T cells.
Conclusions: Here we show for the first time that patients with malignant effusions show a deficient enrichment of T cells expressing the phenotype of type-1-polarized effector T cells at the tumor site. This mechanism is likely to contribute to the escape of tumor cells from immunosurveillance.
AACR